India Proposes New Body With GM-Based Drug Authority
This article was originally published in PharmAsia News
Executive Summary
India's National Biotechnology Regulatory Authority now in the planning stage may be given responsibility for genetically modified drugs, taking them away from the Drug Controller General of India. The DCGI has responsibility for recombinant biologics, DNA vaccines and other GM drugs from the clinical stage to the market. Draft legislation, however, would transfer that purview to the proposed NBRA, whose role would be confined to drugs such as live vaccines containing organisms, but not human insulin or recombinant vaccines derived from, but not containing GMOs. (Click here for more
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.